<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00918749</url>
  </required_header>
  <id_info>
    <org_study_id>2009003</org_study_id>
    <nct_id>NCT00918749</nct_id>
  </id_info>
  <brief_title>Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women</brief_title>
  <official_title>Study Assessing the Efficacy, Safety, and Pharmacokinetics of 75 and 100 mg Once-a-month Delayed-release Risedronate Formulations Compared to 150 mg Once-a-month Immediate-release Risedronate for 3 Months in Postmenopausal Women Age 45-80</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Warner Chilcott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Warner Chilcott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, multicenter, double-blind, double-dummy, active-controlled, parallel-design study
      in approximately 201 postmenopausal women. A subset of subjects (approximately 102) will also
      participate in a pharmacokinetic (PK) component of the study. Each subject will be randomized
      to 1 of 3 treatment regimens for 3 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change From Baseline Serum Type-1 Collagen C-telopeptide (CTX) 75 mg &amp; 100 mg DRFB Tablet Compared With 150 mg IRBB Tablet, Month 4, ITT Population</measure>
    <time_frame>Month 4</time_frame>
    <description>Fasting serum Bone turn-over marker specimen assayed by electochemiluminescence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline CTX 150 mg IRBB Tablet Compared With 75 mg &amp; 100 mg DRFB Tablet, Month 2, ITT Population</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline CTX 150 mg IRBB Tablet Compared With 75 mg &amp; 100 mg DRFB Tablet, Month 3, ITT Population</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Urine NTX (Type-1 Collagen Cross-linked N-telopeptide) Comparing Risedronate 150 mg IRBB Tablet With 75 mg &amp; 100 mg DRFB Tablet, Month 2, ITT Population</measure>
    <time_frame>2 months</time_frame>
    <description>Urine NTX Bone turnover marker collected after 8 hour fast, 2nd voided urine between 6-9 am assayed by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Urine NTX Comparing Risedronate 150 mg IRBB Tablet With 75 mg &amp; 100 mg DRFB Tablet, Month 3, ITT Population</measure>
    <time_frame>3 months</time_frame>
    <description>ITT Population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Urine NTX Comparing Risedronate 150 mg IRBB Tablet With 75 mg &amp; 100 mg DRFB Tablet, Month 4, ITT Population</measure>
    <time_frame>4 months</time_frame>
    <description>ITT Population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Bone Specific Alkaline Phosphatase (BAP) Comparing Risedronate 150 mg IRBB Tablet With 75 mg &amp; 100 mg DRFB Tablet, Month 2, ITT Population</measure>
    <time_frame>2 months</time_frame>
    <description>ITT Population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum BAP Comparing Risedronate 150 mg IRBB Tablet With 75 mg &amp; 100 mg DRFB Tablet, Month 3, ITT Population</measure>
    <time_frame>3 months</time_frame>
    <description>ITT Population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum BAP Comparing Risedronate 150 mg IRBB Tablet With 75 mg &amp; 100 mg DRFB Tablet, Month 4, ITT Population</measure>
    <time_frame>4 months</time_frame>
    <description>ITT Population</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">205</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>150 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>150 mg</intervention_name>
    <description>150 mg immediate release (IRBB) risedronate tablet administered orally at least 30 minutes before breakfast.</description>
    <arm_group_label>150 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>75 mg</intervention_name>
    <description>75 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast</description>
    <arm_group_label>75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg</intervention_name>
    <description>100 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast</description>
    <arm_group_label>100 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female, 45 to 80 years of age, in good general health

          -  postmenopausal ≥2 years, surgically or naturally

          -  body mass index less than or equal to 32 kg/m^2 at screening

        Exclusion Criteria:

          -  no use within 3 months prior, nor use for more than 1 month at any time within 6
             months of: glucocorticoids, anabolic steroids, estrogens, selective estrogen-receptor
             modulators (SERMs), or estrogen-related drugs, progestins, calcitonin, vitamin D
             supplements (&gt;1200 IU per day), calcitriol, calcidiol, or alfacalcidol at any dose,
             any bisphosphonate. fluoride (≥10 mg/day), strontium (≥50 mg/day), parathyroid
             hormone, investigational bone active agents.

          -  allergic or abnormal reactions to bisphosphonates

          -  history of cancer within 5 years, excluding squamous and basal cell carcinoma with 6
             month remission

          -  positive pregnancy test

          -  no depot injection &gt;10,000 IU vitamin D in previous 9 months.

          -  no history of GI disease that requires medication, or history of Crohn's disease,
             ulcerative colitis, diverticular disease, polyps, or surgery that could have changed
             GI structure or motility.

          -  no history of frequent diarrhea or constipation that requires regular laxative use.

          -  no history of alcohol or durg abuse, hyperparathyroidism, cancer previous 5 years,
             major surgery within 1 month prior to screening, diabetes, uncontrolled hypertension,
             cardiovascular, hepatic, renal or GI disease.

          -  no active hyperthyroidism, osteomalacia, use of anticonvulsant medication, or allergic
             reaction to bisphosphonates
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chantell Wilson, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Procter and Gamble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daytona</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ft. Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78727</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2009</study_first_submitted>
  <study_first_submitted_qc>June 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2009</study_first_posted>
  <results_first_submitted>February 23, 2011</results_first_submitted>
  <results_first_submitted_qc>February 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 24, 2011</results_first_posted>
  <last_update_submitted>June 1, 2015</last_update_submitted>
  <last_update_submitted_qc>June 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risedronate Sodium</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Screening began 27 May 2009</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>150 mg</title>
          <description>150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.</description>
        </group>
        <group group_id="P2">
          <title>75 mg</title>
          <description>75 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
        </group>
        <group group_id="P3">
          <title>100 mg</title>
          <description>100 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>ITT (Intent to Treat) Population</title>
              <participants_list>
                <participants group_id="P1" count="69">One subject took no study drug and was not included in ITT Population</participants>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Study Medication Taken</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>150 mg</title>
          <description>150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.</description>
        </group>
        <group group_id="B2">
          <title>75 mg</title>
          <description>75 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
        </group>
        <group group_id="B3">
          <title>100 mg</title>
          <description>100 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="66"/>
            <count group_id="B3" value="69"/>
            <count group_id="B4" value="205"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>ITT Population</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.3" spread="7.2"/>
                    <measurement group_id="B2" value="58.2" spread="7.2"/>
                    <measurement group_id="B3" value="57.5" spread="7.0"/>
                    <measurement group_id="B4" value="58.0" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>ITT Population - Total 204</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 years thru &lt;75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>ITT Population</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian (Oriental)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multi-Racial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hawaiian/Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change From Baseline Serum Type-1 Collagen C-telopeptide (CTX) 75 mg &amp; 100 mg DRFB Tablet Compared With 150 mg IRBB Tablet, Month 4, ITT Population</title>
        <description>Fasting serum Bone turn-over marker specimen assayed by electochemiluminescence.</description>
        <time_frame>Month 4</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>150 mg</title>
            <description>150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.</description>
          </group>
          <group group_id="O2">
            <title>75 mg</title>
            <description>75 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
          </group>
          <group group_id="O3">
            <title>100 mg</title>
            <description>100 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline Serum Type-1 Collagen C-telopeptide (CTX) 75 mg &amp; 100 mg DRFB Tablet Compared With 150 mg IRBB Tablet, Month 4, ITT Population</title>
          <description>Fasting serum Bone turn-over marker specimen assayed by electochemiluminescence.</description>
          <population>ITT Population</population>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.235" spread="2.995"/>
                    <measurement group_id="O2" value="-44.832" spread="3.012"/>
                    <measurement group_id="O3" value="-53.432" spread="3.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A two group t-test with a 0.100 one-sided significance level would have 96% power to detect the difference between a risedronate 150 mg IRBB mean, µ1, of -46.000 and a risedronate 75 mg DRFB mean, µ2, of -29.900 (a difference in means of -16.100), assuming that the common SD was 28.000, with sample sizes of 60 per group, respectively. Estimates were based on Study 2005107 (35 mg DR once a week Phase 2 study). The sample size calculation was not adjusted for multiplicity.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3946</p_value>
            <method>ANOVA</method>
            <method_desc>Fixed effects for treatment and center.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-3.598</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.215</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.568</ci_lower_limit>
            <ci_upper_limit>3.372</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0045</p_value>
            <method>ANOVA</method>
            <method_desc>Fixed effects for treatment and center.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-12.197</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.241</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.208</ci_lower_limit>
            <ci_upper_limit>-5.185</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline CTX 150 mg IRBB Tablet Compared With 75 mg &amp; 100 mg DRFB Tablet, Month 2, ITT Population</title>
        <time_frame>2 months</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>150 mg</title>
            <description>150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.</description>
          </group>
          <group group_id="O2">
            <title>75 mg</title>
            <description>75 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
          </group>
          <group group_id="O3">
            <title>100 mg</title>
            <description>100 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline CTX 150 mg IRBB Tablet Compared With 75 mg &amp; 100 mg DRFB Tablet, Month 2, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.407" spread="3.504"/>
                    <measurement group_id="O2" value="-33.641" spread="3.538"/>
                    <measurement group_id="O3" value="-38.625" spread="3.547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3372</p_value>
            <method>ANOVA</method>
            <method_desc>Fixed effects for treatment and center.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.765</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.952</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.421</ci_lower_limit>
            <ci_upper_limit>12.952</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9650</p_value>
            <method>ANOVA</method>
            <method_desc>Fixed effects for treatment and center.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.218</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.966</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.427</ci_lower_limit>
            <ci_upper_limit>7.991</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline CTX 150 mg IRBB Tablet Compared With 75 mg &amp; 100 mg DRFB Tablet, Month 3, ITT Population</title>
        <time_frame>3 months</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>150 mg</title>
            <description>150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.</description>
          </group>
          <group group_id="O2">
            <title>75 mg</title>
            <description>75 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
          </group>
          <group group_id="O3">
            <title>100 mg</title>
            <description>100 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline CTX 150 mg IRBB Tablet Compared With 75 mg &amp; 100 mg DRFB Tablet, Month 3, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.591" spread="3.045"/>
                    <measurement group_id="O2" value="-35.203" spread="3.034"/>
                    <measurement group_id="O3" value="-46.379" spread="3.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9276</p_value>
            <method>ANOVA</method>
            <method_desc>Fixed effects for treatment and center.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.388</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.269</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.670</ci_lower_limit>
            <ci_upper_limit>7.447</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0133</p_value>
            <method>ANOVA</method>
            <method_desc>Fixed effects for treatment and center.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-10.787</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.313</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.917</ci_lower_limit>
            <ci_upper_limit>-3.657</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Urine NTX (Type-1 Collagen Cross-linked N-telopeptide) Comparing Risedronate 150 mg IRBB Tablet With 75 mg &amp; 100 mg DRFB Tablet, Month 2, ITT Population</title>
        <description>Urine NTX Bone turnover marker collected after 8 hour fast, 2nd voided urine between 6-9 am assayed by ELISA.</description>
        <time_frame>2 months</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>150 mg</title>
            <description>150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.</description>
          </group>
          <group group_id="O2">
            <title>75 mg</title>
            <description>75 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
          </group>
          <group group_id="O3">
            <title>100 mg</title>
            <description>100 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Urine NTX (Type-1 Collagen Cross-linked N-telopeptide) Comparing Risedronate 150 mg IRBB Tablet With 75 mg &amp; 100 mg DRFB Tablet, Month 2, ITT Population</title>
          <description>Urine NTX Bone turnover marker collected after 8 hour fast, 2nd voided urine between 6-9 am assayed by ELISA.</description>
          <population>ITT Population</population>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.365" spread="6.567"/>
                    <measurement group_id="O2" value="-0.837" spread="6.631"/>
                    <measurement group_id="O3" value="-1.150" spread="6.689"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1192</p_value>
            <method>ANOVA</method>
            <method_desc>Fixed effects for treatment and center.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>14.528</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.280</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.813</ci_lower_limit>
            <ci_upper_limit>29.868</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1298</p_value>
            <method>ANOVA</method>
            <method_desc>Fixed effects for treatment and center.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>14.215</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.343</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.230</ci_lower_limit>
            <ci_upper_limit>29.659</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Urine NTX Comparing Risedronate 150 mg IRBB Tablet With 75 mg &amp; 100 mg DRFB Tablet, Month 3, ITT Population</title>
        <description>ITT Population</description>
        <time_frame>3 months</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>150 mg</title>
            <description>150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.</description>
          </group>
          <group group_id="O2">
            <title>75 mg</title>
            <description>75 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
          </group>
          <group group_id="O3">
            <title>100 mg</title>
            <description>100 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Urine NTX Comparing Risedronate 150 mg IRBB Tablet With 75 mg &amp; 100 mg DRFB Tablet, Month 3, ITT Population</title>
          <description>ITT Population</description>
          <population>ITT Population</population>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.673" spread="4.351"/>
                    <measurement group_id="O2" value="-20.555" spread="4.326"/>
                    <measurement group_id="O3" value="-29.066" spread="4.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8546</p_value>
            <method>ANOVA</method>
            <method_desc>Fixed effects for treatment and center.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.119</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.093</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.956</ci_lower_limit>
            <ci_upper_limit>11.193</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2291</p_value>
            <method>ANOVA</method>
            <method_desc>Fixed effects for treatment and center.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-7.393</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.126</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.522</ci_lower_limit>
            <ci_upper_limit>2.737</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Urine NTX Comparing Risedronate 150 mg IRBB Tablet With 75 mg &amp; 100 mg DRFB Tablet, Month 4, ITT Population</title>
        <description>ITT Population</description>
        <time_frame>4 months</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>150 mg</title>
            <description>150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.</description>
          </group>
          <group group_id="O2">
            <title>75 mg</title>
            <description>75 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
          </group>
          <group group_id="O3">
            <title>100 mg</title>
            <description>100 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Urine NTX Comparing Risedronate 150 mg IRBB Tablet With 75 mg &amp; 100 mg DRFB Tablet, Month 4, ITT Population</title>
          <description>ITT Population</description>
          <population>ITT Population</population>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.447" spread="6.427"/>
                    <measurement group_id="O2" value="-7.942" spread="6.464"/>
                    <measurement group_id="O3" value="-14.360" spread="6.492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5436</p_value>
            <method>ANOVA</method>
            <method_desc>Fixed effects for treatment and center.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>5.505</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.046</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.452</ci_lower_limit>
            <ci_upper_limit>20.462</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9201</p_value>
            <method>ANOVA</method>
            <method_desc>Fixed effects for treatment and center.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.914</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.100</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.959</ci_lower_limit>
            <ci_upper_limit>14.132</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Bone Specific Alkaline Phosphatase (BAP) Comparing Risedronate 150 mg IRBB Tablet With 75 mg &amp; 100 mg DRFB Tablet, Month 2, ITT Population</title>
        <description>ITT Population</description>
        <time_frame>2 months</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>150 mg</title>
            <description>150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.</description>
          </group>
          <group group_id="O2">
            <title>75 mg</title>
            <description>75 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
          </group>
          <group group_id="O3">
            <title>100 mg</title>
            <description>100 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Bone Specific Alkaline Phosphatase (BAP) Comparing Risedronate 150 mg IRBB Tablet With 75 mg &amp; 100 mg DRFB Tablet, Month 2, ITT Population</title>
          <description>ITT Population</description>
          <population>ITT Population</population>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.457" spread="2.867"/>
                    <measurement group_id="O2" value="-2.349" spread="2.895"/>
                    <measurement group_id="O3" value="-0.615" spread="2.902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4440</p_value>
            <method>ANOVA</method>
            <method_desc>Fixed effects for treatment and center.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.108</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.052</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.590</ci_lower_limit>
            <ci_upper_limit>9.807</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2349</p_value>
            <method>ANOVA</method>
            <method_desc>Fixed effects for treatment and center.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.842</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.063</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.874</ci_lower_limit>
            <ci_upper_limit>11.559</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum BAP Comparing Risedronate 150 mg IRBB Tablet With 75 mg &amp; 100 mg DRFB Tablet, Month 3, ITT Population</title>
        <description>ITT Population</description>
        <time_frame>3 months</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>150 mg</title>
            <description>150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.</description>
          </group>
          <group group_id="O2">
            <title>75 mg</title>
            <description>75 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
          </group>
          <group group_id="O3">
            <title>100 mg</title>
            <description>100 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Serum BAP Comparing Risedronate 150 mg IRBB Tablet With 75 mg &amp; 100 mg DRFB Tablet, Month 3, ITT Population</title>
          <description>ITT Population</description>
          <population>ITT Population</population>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.797" spread="3.087"/>
                    <measurement group_id="O2" value="-12.831" spread="3.075"/>
                    <measurement group_id="O3" value="-12.872" spread="3.119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2527</p_value>
            <method>ANOVA</method>
            <method_desc>Fixed effects for treatment and center.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.966</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.327</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.189</ci_lower_limit>
            <ci_upper_limit>12.120</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2613</p_value>
            <method>ANOVA</method>
            <method_desc>Fixed effects for treatment and center.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.926</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.371</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.301</ci_lower_limit>
            <ci_upper_limit>12.153</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum BAP Comparing Risedronate 150 mg IRBB Tablet With 75 mg &amp; 100 mg DRFB Tablet, Month 4, ITT Population</title>
        <description>ITT Population</description>
        <time_frame>4 months</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>150 mg</title>
            <description>150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.</description>
          </group>
          <group group_id="O2">
            <title>75 mg</title>
            <description>75 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
          </group>
          <group group_id="O3">
            <title>100 mg</title>
            <description>100 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Serum BAP Comparing Risedronate 150 mg IRBB Tablet With 75 mg &amp; 100 mg DRFB Tablet, Month 4, ITT Population</title>
          <description>ITT Population</description>
          <population>ITT Population</population>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.885" spread="2.956"/>
                    <measurement group_id="O2" value="-19.616" spread="2.973"/>
                    <measurement group_id="O3" value="-23.710" spread="2.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7606</p_value>
            <method>ANOVA</method>
            <method_desc>Fixed effects for treatment and center.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.269</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.160</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.609</ci_lower_limit>
            <ci_upper_limit>8.148</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5006</p_value>
            <method>ANOVA</method>
            <method_desc>Fixed effects for treatment and center.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.825</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.185</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.744</ci_lower_limit>
            <ci_upper_limit>4.095</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>27 May 2009 thru 23 October 2009, 5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>150 mg</title>
          <description>150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.</description>
        </group>
        <group group_id="E2">
          <title>75 mg</title>
          <description>75 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
        </group>
        <group group_id="E3">
          <title>100 mg</title>
          <description>100 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="69"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="66"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="66"/>
                <counts group_id="E3" events="19" subjects_affected="14" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Abnormal Faeces</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Frequent Bowel Movements</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle Strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="11" subjects_affected="7" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Joint Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="69"/>
                <counts group_id="E2" events="27" subjects_affected="15" subjects_at_risk="66"/>
                <counts group_id="E3" events="25" subjects_affected="18" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Oopharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Grexan Wulff, Manager, Regulatory Affairs</name_or_title>
      <organization>Warner Chilcott</organization>
      <phone>973-442-3376</phone>
      <email>gwulff@wcrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

